Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma

Yukio Watanabe, Kouya Shiraishi, Fumiaki Takahashi, Akihiko Yoshida, Kenji Suzuki, Hisao Asamura, Masahiro Takeuchi, Koh Furuta, Koji Tsuta

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: Pulmonary adenosquamous carcinoma (ASC) is more aggressive than adenocarcinoma (AC) and squamous cell carcinoma (SCC). The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC. Methods and results: Surgically resected ASC samples from 65 patients were analysed. We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements. Gene amplification and expression of EGFR, human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor-1 and MET were also examined. β III-Tubulin showed the highest expression (P = 0.002), and its expression was more frequent in the AC than in the SCC component (P = 0.013). RRM1 expression was more frequent in the SCC component (P = 0.046). EGFR and KRAS mutations were detected in both components (21.5 and 10.9%, respectively). ALK and ROS1 rearrangements and MET amplification were detected in both components in one (1.5%) case. Conclusions: In ASC, drug response-specific gene alterations could occur in both AC and SCC components, suggesting that patients with confirmed or suspected ASC should undergo further testing for driver gene analyses. Copyright

Original languageEnglish
Pages (from-to)939-948
Number of pages10
JournalHistopathology
Volume66
Issue number7
DOIs
Publication statusPublished - 2015 Jun 1
Externally publishedYes

Fingerprint

Adenosquamous Carcinoma
Biomarkers
Gene Expression
Lung
Squamous Cell Carcinoma
Cellular Structures
Epidermal Growth Factor Receptor
Ribonucleotide Reductases
Adenocarcinoma
Tubulin
Therapeutics
Receptor, Fibroblast Growth Factor, Type 1
Thymidylate Synthase
Mutation
Gene Amplification
Neoplasm Genes
Genes
Breast Neoplasms
Pharmaceutical Preparations

Keywords

  • Adenosquamous carcinoma
  • Biomarker expression
  • Druggable gene alterations

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma. / Watanabe, Yukio; Shiraishi, Kouya; Takahashi, Fumiaki; Yoshida, Akihiko; Suzuki, Kenji; Asamura, Hisao; Takeuchi, Masahiro; Furuta, Koh; Tsuta, Koji.

In: Histopathology, Vol. 66, No. 7, 01.06.2015, p. 939-948.

Research output: Contribution to journalArticle

Watanabe, Y, Shiraishi, K, Takahashi, F, Yoshida, A, Suzuki, K, Asamura, H, Takeuchi, M, Furuta, K & Tsuta, K 2015, 'Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma', Histopathology, vol. 66, no. 7, pp. 939-948. https://doi.org/10.1111/his.12556
Watanabe, Yukio ; Shiraishi, Kouya ; Takahashi, Fumiaki ; Yoshida, Akihiko ; Suzuki, Kenji ; Asamura, Hisao ; Takeuchi, Masahiro ; Furuta, Koh ; Tsuta, Koji. / Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma. In: Histopathology. 2015 ; Vol. 66, No. 7. pp. 939-948.
@article{e522d9d6ea8946dcacb9f28a597615e1,
title = "Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma",
abstract = "Aims: Pulmonary adenosquamous carcinoma (ASC) is more aggressive than adenocarcinoma (AC) and squamous cell carcinoma (SCC). The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC. Methods and results: Surgically resected ASC samples from 65 patients were analysed. We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements. Gene amplification and expression of EGFR, human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor-1 and MET were also examined. β III-Tubulin showed the highest expression (P = 0.002), and its expression was more frequent in the AC than in the SCC component (P = 0.013). RRM1 expression was more frequent in the SCC component (P = 0.046). EGFR and KRAS mutations were detected in both components (21.5 and 10.9{\%}, respectively). ALK and ROS1 rearrangements and MET amplification were detected in both components in one (1.5{\%}) case. Conclusions: In ASC, drug response-specific gene alterations could occur in both AC and SCC components, suggesting that patients with confirmed or suspected ASC should undergo further testing for driver gene analyses. Copyright",
keywords = "Adenosquamous carcinoma, Biomarker expression, Druggable gene alterations",
author = "Yukio Watanabe and Kouya Shiraishi and Fumiaki Takahashi and Akihiko Yoshida and Kenji Suzuki and Hisao Asamura and Masahiro Takeuchi and Koh Furuta and Koji Tsuta",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/his.12556",
language = "English",
volume = "66",
pages = "939--948",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma

AU - Watanabe, Yukio

AU - Shiraishi, Kouya

AU - Takahashi, Fumiaki

AU - Yoshida, Akihiko

AU - Suzuki, Kenji

AU - Asamura, Hisao

AU - Takeuchi, Masahiro

AU - Furuta, Koh

AU - Tsuta, Koji

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Aims: Pulmonary adenosquamous carcinoma (ASC) is more aggressive than adenocarcinoma (AC) and squamous cell carcinoma (SCC). The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC. Methods and results: Surgically resected ASC samples from 65 patients were analysed. We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements. Gene amplification and expression of EGFR, human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor-1 and MET were also examined. β III-Tubulin showed the highest expression (P = 0.002), and its expression was more frequent in the AC than in the SCC component (P = 0.013). RRM1 expression was more frequent in the SCC component (P = 0.046). EGFR and KRAS mutations were detected in both components (21.5 and 10.9%, respectively). ALK and ROS1 rearrangements and MET amplification were detected in both components in one (1.5%) case. Conclusions: In ASC, drug response-specific gene alterations could occur in both AC and SCC components, suggesting that patients with confirmed or suspected ASC should undergo further testing for driver gene analyses. Copyright

AB - Aims: Pulmonary adenosquamous carcinoma (ASC) is more aggressive than adenocarcinoma (AC) and squamous cell carcinoma (SCC). The genetic features and biomarkers of ASC are not well known. Here, we attempted to identify potential therapeutic markers for ASC. Methods and results: Surgically resected ASC samples from 65 patients were analysed. We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements. Gene amplification and expression of EGFR, human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor-1 and MET were also examined. β III-Tubulin showed the highest expression (P = 0.002), and its expression was more frequent in the AC than in the SCC component (P = 0.013). RRM1 expression was more frequent in the SCC component (P = 0.046). EGFR and KRAS mutations were detected in both components (21.5 and 10.9%, respectively). ALK and ROS1 rearrangements and MET amplification were detected in both components in one (1.5%) case. Conclusions: In ASC, drug response-specific gene alterations could occur in both AC and SCC components, suggesting that patients with confirmed or suspected ASC should undergo further testing for driver gene analyses. Copyright

KW - Adenosquamous carcinoma

KW - Biomarker expression

KW - Druggable gene alterations

UR - http://www.scopus.com/inward/record.url?scp=84929133909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929133909&partnerID=8YFLogxK

U2 - 10.1111/his.12556

DO - 10.1111/his.12556

M3 - Article

VL - 66

SP - 939

EP - 948

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 7

ER -